Siemens IMMULITE 2000 Manuel D'instructions page 8

Specificity
ng/mL
1
Compound Added
Adrenosterone
Aldosterone 10,000
5β-Androstan-3α,17β-diol 1,000
Δ
4 -Androsten-11β-ol-3,17-
dione
Androsterone
Cholesterol 1,000
Corticosterone 1,000
Cortisol 10,000
Cortisone 6,000
Dexamethasone 1,000
DHEA
DHEA-SO 2000
4
Deoxycorticosterone 10,000
Estradiol-17β 10,000
Estriol 1,000
Estrone 1,000
11-Ketotestosterone 1,500
Norethindrone 1,000
17α-Hydroxyprogesterone 10,000
Pregnenolone 10,000
2500
Prednisone 1,000
Progesterone 1,000
Spironolactone 1,000
5α-Dihydrotestosterone 1,000
Testosterone
ND: not detectable 5
Method Comparison 1
7
6
5
4
3
2
1
0
0 1 2 3
Kit A, ng/m L
(IML 2000) = 1.12 (Kit A) – 0.45 ng/mL
r = 0.950
8
Apparent % Cross-
2 3 4
ng/mL reactivity
30 2.93 9.8%
ND ND
ND ND
50 1.6 3.2%
500 2.92 0.584%
ND ND
ND ND
0.67 0.007%
1.44 0.023%
ND ND
7 0.38 5.4%
ND ND
6.7 0.07%
0.31 0.003%
ND ND
ND ND
1.21 0.081%
0.49 0.049%
9.88 0.1%
150 ND ND
0.33 0.003%
ND ND
0.47 0.047%
2.95 0.295%
5.37 0.54%
100 2.31 2.31%
2.01 0.201%
100 1.37 1.4%
4 5 6 7
Method Comparison 2
10
8
6
4
2
0
0 2 4
IMMULITE Androstenedione, ng/mL
(IML 2000) = 0.94 (IML) – 0.05 ng/mL
r = 0.992
1
Intra-Assay,
Deutsch. Precision:
3 Mittelwert, 4 SD (Standardabweichung),
(Variationskoeffizient). Linearity:
2 Beobachtet (B), 3 Erwartet (E),
1 Lösung, 2 Beobachtet (B),
Recovery:
4
(E), % B/E. Specificity:
2 zugesetzte Menge, 3 Gemessene Konzentration,
4 5
% Kreuzreaktivität, NN: Nicht nachweisbar.
1 Konjugiertes,
Effect of Bilirubin:
2 3
Unkonjugiertes, Ohne Zugabe von. Effect of
1 Hämoglobin,
Hemolysis:
1 Triglyceride Menge,
Lipemia:
3 4
Erwartet (E), % B/E. Method Comparison:
ZEngKitName: Androstendion.
1
Intraensayo,
Español. Precision:
3 Media, 4 DS, 5 CV. Linearity:
2 3
Observado (O), Esperado (E),
1 Solución, 2 Observado (O),
Recovery:
3 4
Esperado (E), %O/E. Specificity:
1 Compuesto, 2 Cantidad añadida,
4
aparente, % Reacción cruzada,
detectable. Effect of Bilirubin:
2 libre, 3 Sin añadir. Effect of Hemolysis:
1 2
Hemoglobina, Sin añadir. Lipemia:
1 Triglicéridos añadida, 2 Observado (O),
3 4
Esperado (E), %O/E. Method Comparison:
ZEngKitName: Androstenodiona.
1
Intraessai,
Français. Precision:
3 Moyenne, 4 SD, 5 CV. Linearity:
2 3
Observé (O), Attendu (A),
1 2
Solution, Observé (O),
Recovery:
(A), 4 %O/A. Specificity: 1
3
Concentration apparente,
5 ND: non détectable. Effect of Bilirubin:
1 2
Conjuguée, Non conjuguée,
1 Hémoglobine,
Effect of Hemolysis:
1
chargés. Lipemia: Triglycérides ajouté,
2 3
Observé (O), Attendu (A),
Comparison: ZEngKitName: Androstènedione.
1 Intra-serie,
Italiano. Precision:
4
SD (Deviazione Standard),
Variazione). Linearity: 1 Diluizione,
(O), 3 Atteso (A), 4 %O/A, 5
1 2
Soluzione, Osservato (O),
IMMULITE 2000 Androstenedione (PIL2KAO-23, 2021-04)
6 8 10
2
Gesamt,
5 CV
1
Verdünnung,
4 % B/E, 5 8 in 8.
3 Erwartet
1
Verbindung,
2 Ohne Zugabe von.
2 Beobachtet (B),
2
Total,
1 Dilución,
4 5
%O/E, 8 en 8.
3 Concentración
5
ND: no
1
conjugada,
2
Total,
1 Dilution,
4 5
%O/A, 8 dans 8.
3
Attendu
Composé, 2 ajouté,
4
Réaction croisée %,
3
Non chargés.
2 Non
4
%O/A. Method
2 Totale, 3 Media,
5
CV (Coefficiente di
2 Osservato
8 in 8. Recovery:
3 4
Atteso (A), %O/A.